Intellia Therapeutics - NTLA Stock Forecast, Price & News

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics Trading Down 6.2 %

Shares of Intellia Therapeutics stock traded down $4.25 on Tuesday, reaching $64.17. 995,310 shares of the company were exchanged, compared to its average volume of 1,214,870. The company has a market capitalization of $4.88 billion, a price-to-earnings ratio of -11.99 and a beta of 2.00. Intellia Therapeutics has a one year low of $37.08 and a one year high of $180.59. The company has a 50-day moving average of $58.13 and a 200 day moving average of $63.14.

Intellia Therapeutics (NASDAQ:NTLA - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.03). Intellia Therapeutics had a negative net margin of 883.17% and a negative return on equity of 40.23%. The firm had revenue of $14.00 million during the quarter, compared to analyst estimates of $9.50 million. During the same quarter in the prior year, the business earned ($1.01) EPS. The business's revenue was up 115.4% compared to the same quarter last year. Analysts predict that Intellia Therapeutics will post -5.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on NTLA shares. Chardan Capital cut their target price on Intellia Therapeutics from $172.00 to $146.00 and set a "buy" rating on the stock in a research note on Friday, August 5th. Credit Suisse Group lifted their price target on shares of Intellia Therapeutics to $101.00 in a research report on Tuesday, August 9th. The Goldman Sachs Group lowered their price objective on shares of Intellia Therapeutics from $206.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Friday, August 5th. Finally, JMP Securities lowered their price target on Intellia Therapeutics from $165.00 to $110.00 in a report on Monday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $128.00.